July 2017 in “OPAL (Open@LaTrobe) (La Trobe University)” In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.
July 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This study introduced the BASP classification, a new system for categorizing pattern hair loss in both men and women, and applied it to analyze 2213 Korean subjects.
1 citations
,
July 2017 in “The Journal of Urology” In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.
October 2022 in “Rheumatology (Bulgaria)” This case report details the challenging diagnostic journey of a 50-year-old woman with progressive supranuclear palsy, highlighting the disease's complex and variable clinical presentation.
5 citations
,
August 2005 in “Current Urology Reports” Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.
This study found that patients with psoriasis had a significantly higher prevalence of autoimmune diseases and other comorbidities compared to individuals without psoriasis.
8 citations
,
April 2008 in “The Journal of Urology” This commentary discusses the public health implications of benign prostatic hyperplasia (BPH) and provides no new research results.
14 citations
,
January 2019 in “Skin appendage disorders” This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.
April 2011 in “Journal of physiology and pharmacology : an official journal of the Polish Physiological Society” This study found that drug adherence rates in men with benign prostatic hyperplasia were low, decreasing with longer treatment duration, and were higher in patients with more severe symptoms.
March 2026 in “The Aging Male” This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.
18 citations
,
September 1972 in “British Journal of Pharmacology” In this study on male rats, parachlorophenylalanine treatment induced hypersexual behavior and hair loss linked to increased social interaction but had no effect on brain serotonin when testosterone was used instead.
April 2020 in “Journal of the Endocrine Society” This case report highlights the importance of considering pituitary stalk interruption syndrome as a potential diagnosis for patients with short stature, as early detection may allow those affected to achieve normal height.
July 2023 in “Journal of exploratory research in pharmacology” In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.
July 2004 in “Current Urology Reports”
7 citations
,
January 2019 in “The Aging Male” This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
7 citations
,
April 2024 in “Skin Research and Technology” This study found that ChatGPT provided fairly accurate answers to common psoriasis-related questions, as rated by medical experts, although it doesn't fully replace professional medical judgment or diagnosis.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
1 citations
,
November 2022 in “Journal of the Academy of Consultation-Liaison Psychiatry” This case study reports on a 44-year-old male exhibiting persistent neuropsychiatric symptoms described as Post-Finasteride Syndrome after discontinuing long-term finasteride use, highlighting the ongoing debate regarding its classification as a true disease process.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
December 2006 in “Lancet Oncology” In men aged 40–60 years with androgenic alopecia, this study found that 1 mg/day finasteride reduced serum PSA concentrations by 40-50% after 48 weeks compared to placebo.
April 2025 in “Sabuncuoglu Serefeddin Health Sciences” This study highlights the public health significance of androgenic-anabolic steroid use disorder, emphasizing health risks, societal effects, and the need for routine AAS analyses in forensic autopsies, especially in athlete deaths.
April 2020 in “The Journal of Urology” This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.
5 citations
,
June 2015 in “British Journal of Dermatology” This article discusses the role of lysophosphatidic acid-induced histamine release in generalized pruritus among patients with primary sclerosing cholangitis and reports no new clinical results.
June 2026 in “Value in Health” 8 citations
,
May 2016 in “Indian Journal of Pharmacology” This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.
November 2023 in “Frontiers in Neuroendocrinology” This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.
14 citations
,
June 2015 in “Toxicology and Industrial Health” This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.